Sarepta Therapeutics suffered another major setback on Friday as Europe's drug regulator decided not to recommend the ...

Sarepta Therapeutics' brutal week continued Friday after European officials rejected the company's controversial gene therapy ...

Separately, Sareptea said last week that it would pause the development of most of its experimental gene therapies for a different type of muscular dystrophy. The stoppage came after one of the ...

Sarepta Therapeutics (SRPT) stock drops as the company faces potential FDA-mandated studies after safety concerns over its ...

As gene therapy maker Sarepta Therapeutics tangles with FDA over its Duchenne treatment, patients and their families are ...

European regulators said that a Duchenne gene therapy should not be approved, imperiling the treatment that is also facing ...

Sarepta stock plunged again Thursday on a report the FDA will require additional clinical testing to validate the safety ...

Wall Street is ending the week on a quiet note, with stocks hovering near their all-time highs as traders digest the latest ...

Stocks rose toward all-time highs as Alphabet Inc.’s results showed solid demand for artificial intelligence, bolstering ...